-
Mashup Score: 3FDA Approves Revumenib in KMT2A-Rearranged Acute Leukemia - 7 hour(s) ago
Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6FDA Approves Zanidatamab for Previously Treated, Unresectable or Metastatic HER2+ Biliary Tract Cancer - 8 hour(s) ago
The FDA has granted accelerated approval to zanidatamab for pretreated, advanced HER2-positive biliary tract cancer.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet-
FDA Approves Zanidatamab for Previously Treated, Unresectable or Metastatic HER2+ Biliary Tract Cancer https://t.co/CQj6W9MzE5 via @onclive
-
-
Mashup Score: 3FDA Approves Revumenib in KMT2A-Rearranged Acute Leukemia - 6 day(s) ago
Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia.
Source: www.targetedonc.comCategories: General Medicine News, Hem/OncsTweet-
FDA Approves Revumenib in KMT2A-Rearranged Acute Leukemia https://t.co/piSiDmAmlY via @targetedonc
-
-
Mashup Score: 1Four Tech Scale-Ups Win Unicorn Pathfinder Awards - 6 day(s) ago
The UK Government has announced four tech scale up businesses as winners of the Unicorn Kingdom Pathfinder Awards.
Source: www.digit.fyiCategories: General Medicine News, Hem/OncsTweet-
Four Tech Scale-Ups Win Unicorn Pathfinder Awards https://t.co/AlCdtkAqPC via @digitfyi
-
-
Mashup Score: 20Homepage of Mark Cuban Cost Plus Drugs - 10 day(s) ago
Mark Cuban Cost Plus Drug homepage. Provides safe, affordable medicine or medication with transparent low prices.
Source: costplusdrugs.comCategories: General Medicine News, Hem/OncsTweet-
RT @mcuban: @regohurtado @askslim I'm focused on https://t.co/LYIIV9PYoL and what we can do from there. If we can make this work like we…
-
-
Mashup Score: 3Yan Leyfman: Honored to present our research at the 2024 Lymphoma, Leukemia and Myeloma Congress - OncoDaily - 19 day(s) ago
Yan Leyfman: Honored to present our research at the 2024 Lymphoma, Leukemia and Myeloma Congress / cancer, Chandler Park, Icahn School of Medicine, Lymphoma
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: Honored to present our research at the 2024 @llmcongress - @YLeyfman https://t.co/435ujH7EJy #Cancer #LLMC24 #MedEd #MedN…
-
-
Mashup Score: 1
Théo is controlling the election speculation on Polymarket with massive bets of nearly all his liquid net worth.
Source: mishtalk.comCategories: General Medicine News, Hem/OncsTweet-
LOL the polymarket whale is a French guy betting $30M out of hopium https://t.co/vdF7Cf8APl
-
-
Mashup Score: 1Arturo LoAIza-Bonilla: Excited to Join the Conversation at Google’s AI in Oncology Summit - OncoDaily - 20 day(s) ago
Arturo LoAIza-Bonilla: Excited to Join the Conversation at Google’s AI in Oncology Summit / AI, Arturo Loaiza-Bonilla, cancer, Google, Google’s AI in Oncology
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: Excited to Join the Conversation at @Google’s AI in Oncology Summit - @DrBonillaOnc @MassiveBio https://t.co/uGyE0SuSZn…
-
-
Mashup Score: 1Oracle to launch new EHR system - 23 day(s) ago
“Discover Oracle’s new AI-powered EHR system, designed to simplify usage and setup with cloud and AI features. Available in 2025, it aims to revolutionize healt
Source: www.beckershospitalreview.comCategories: General Medicine News, Hem/OncsTweet-
Oracle to launch new EHR system https://t.co/KBJJnqqLYv @Oracle
-
-
Mashup Score: 12Engage in ASCO's Advocacy Efforts - 24 day(s) ago
Write a letter to your lawmaker today!
Source: asco.quorum.usCategories: General Medicine News, Hem/OncsTweet-
Thanks, @ASCO for naming me an Advocacy Champion for my continued commitment to advocating for issues affecting the #oncology community. You can be an Advocacy Champion too by getting involved today: https://t.co/6SqgQTFHGf #ASCOAdvocacySummit @capitalhealthnj @MassiveBio… https://t.co/pjOZrxaBP4 https://t.co/ClpJq5pyF5
-
FDA Approves Revumenib in KMT2A-Rearranged Acute Leukemia https://t.co/piSiDmAmlY via @targetedonc